<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2D08B3B4-46BE-467D-8644-AEF99777FE88"><gtr:id>2D08B3B4-46BE-467D-8644-AEF99777FE88</gtr:id><gtr:name>Los Angeles Institute of Allergy and Clinical Immunology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0FD01CC2-BEC0-446C-B6B3-492C7AEEBAD6"><gtr:id>0FD01CC2-BEC0-446C-B6B3-492C7AEEBAD6</gtr:id><gtr:name>Southampton General Hospital</gtr:name><gtr:address><gtr:line1>Southampton General Hospital</gtr:line1><gtr:line2>Tremona Road</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EB666EBF-9863-4DD2-8D1C-36D8ADA89453"><gtr:id>EB666EBF-9863-4DD2-8D1C-36D8ADA89453</gtr:id><gtr:name>Graduate School of Biomedical &amp; Health Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4466227F-8EEC-49F2-9ACA-D7CACF5FD8CF"><gtr:id>4466227F-8EEC-49F2-9ACA-D7CACF5FD8CF</gtr:id><gtr:name>Sanguine Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:line4>Ghent</gtr:line4><gtr:line5>B-9000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Randall Div of Cell and Molecular Biophy</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2D08B3B4-46BE-467D-8644-AEF99777FE88"><gtr:id>2D08B3B4-46BE-467D-8644-AEF99777FE88</gtr:id><gtr:name>Los Angeles Institute of Allergy and Clinical Immunology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0FD01CC2-BEC0-446C-B6B3-492C7AEEBAD6"><gtr:id>0FD01CC2-BEC0-446C-B6B3-492C7AEEBAD6</gtr:id><gtr:name>Southampton General Hospital</gtr:name><gtr:address><gtr:line1>Southampton General Hospital</gtr:line1><gtr:line2>Tremona Road</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EB666EBF-9863-4DD2-8D1C-36D8ADA89453"><gtr:id>EB666EBF-9863-4DD2-8D1C-36D8ADA89453</gtr:id><gtr:name>Graduate School of Biomedical &amp; Health Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4466227F-8EEC-49F2-9ACA-D7CACF5FD8CF"><gtr:id>4466227F-8EEC-49F2-9ACA-D7CACF5FD8CF</gtr:id><gtr:name>Sanguine Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:line4>Ghent</gtr:line4><gtr:line5>B-9000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B8DE35C1-BD77-40C7-A617-698BD33A5AB7"><gtr:id>B8DE35C1-BD77-40C7-A617-698BD33A5AB7</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Sutton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8221B3D6-BC50-4D27-BD59-6ED3EDE76F2A"><gtr:id>8221B3D6-BC50-4D27-BD59-6ED3EDE76F2A</gtr:id><gtr:firstName>Rainer</gtr:firstName><gtr:surname>Heintzmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1A92AD5A-28CF-4D01-81D6-532BEEE07B30"><gtr:id>1A92AD5A-28CF-4D01-81D6-532BEEE07B30</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Beavil</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C68DCAD6-AB77-43CC-AEAF-45EB93348FA8"><gtr:id>C68DCAD6-AB77-43CC-AEAF-45EB93348FA8</gtr:id><gtr:firstName>Hannah</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Gould</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501494"><gtr:id>C45F2ED4-D112-4F62-B32B-DBA69DF27BF3</gtr:id><gtr:title>Exploring, Understanding and Intervening in IgE-dependent Mechanisms in Allergic Disease and Asthma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501494</gtr:grantReference><gtr:abstractText>The incidence of allergic disease, and asthma in particular, has increased alarmingly in the UK and there is an urgent need for new therapies. Antibodies of a type known as immunoglobulin E (IgE) are crucially involved in the allergic response, and individuals susceptible to allergies have high IgE levels. These IgE antibodies recognise allergens that enter the airways (e.g. grass pollen), the gut (food allergens) or the skin (contact allergies), and then trigger allergic reactions. We know, from the success of an anti-IgE treatment, that removal of IgE relieves allergic symptoms. But anti-IgE, itself an antibody, is very expensive, requires administration in the clinic, and is licensed only for severe asthma. By understanding how the body produces IgE, and the way IgE activates allergic reactions, we expect to discover new ways to inhibit IgE, and develop compounds that are cheaper, more widely applicable to different allergic conditions, and easier to administer. 

The cells in the body that make antibodies, B-cells, switch in response to certain signals from producing beneficial, protective antibodies to producing IgE; our aim is to understand and prevent this switch. We have discovered that switching can occur in the nose rather than, as previously thought, only in lymph nodes, and now, using nasal tissue available from a surgical procedure (to clear nasal passages) developed at Guy?s Hospital, we can study the process in detail. We shall use an ultra-high resolution microscope (the first of its kind in the UK) to study events within the B-cell nucleus as the genes for IgE are switched on, and then study the survival and proliferation of these IgE-producing cells. This work will undoubtedly identify new targets for intervention.

We have also discovered that ?superantigens?, bacterial molecules that trigger antibody production, are present in asthmatic patients? airways. We believe that these superantigens may promote IgE production, in the lung or nose, and will study how they interact with IgE ? opening up a new approach to allergy treatment. We will also investigate the claim that certain IgE molecules are more active than others in triggering allergy. We have already determined the molecular structure of IgE and found that it changes its shape when it triggers an allergic reaction. We can now test compounds that prevent this change in shape, collaborating with the pharmaceutical industry to develop small-molecule inhibitors that overcome the limitations of anti-IgE.</gtr:abstractText><gtr:technicalSummary>The IgE antibody is a central element in the allergic response and the aetiology of asthma. Our proposed research is predicated on the existing evidence that IgE is an effective therapeutic target. The options include suppression of IgE synthesis and the interactions of IgE with its receptors, with allergens and with superantigens. We plan to address the following questions: 
1. Since we know that heavy-chain chain switching to IgE occurs locally in the target organs of allergy, we need next to complement our biochemical studies on regulation of switching to IgE by imaging of the genes and associated proteins. Cell biological investigations of this kind have been limited by the resolution of commercial confocal microscopes, but a new instrument constructed here gives an unprecedented improvement in resolution, thus bringing it into the required range. 
2. Thanks to a new surgical technique of turbinectomy developed at Guy?s Hospital by our collaborator, we can now explore the mechanisms by which the B-cells in the nasal mucosa are driven to synthesise and secrete IgE. We will also isolate single plasma cells secreting IgE antibodies directed against aeroallergens and S. aureus superantigens, clone and express their light-chain and epsilon heavy-chain genes and prepare recombinant IgE antibodies for structural studies.
3. We have discovered that bacterial superantigens are involved in the pathogenesis of allergic disease. We will explore the details of allergen- and superantigen-IgE interactions by X-ray crystallography (cf. our earlier X-ray structures of IgE and superantigen-antibody complexes). 
4. We wish to uncover the structural basis for mast cell signalling triggered by monomeric murine IgE in the absence of antigen (with the collaboration of two groups in the US), and to survey our recombinant human IgEs for similar activity. The outcome will throw light on the relevance of ?highly cytokinergic? IgE to the pathogenesis of allergy. 
5. We plan to develop a new generation of inhibitors to target the conformational change that the IgE molecule undergoes upon interaction with its high-affinity receptor, FceRI. We shall investigate the mechanism of action of peptide and other inhibitors, and anti-IgE Fabs, by structural and biophysical methods to ascertain whether they affect the conformational change. These results will provide a basis for design of inhibitors through collaboration with the pharmaceutical industry.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-20</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-06-21</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2294565</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Novartis</gtr:description><gtr:id>36F07BDD-92BF-4D00-A613-56D5147FC4CF</gtr:id><gtr:impact>A clinical trial has been initiated as a result of the collaboration; additional funding was obtained from other sources; understanding of role of IgE in non-atopic asthma</gtr:impact><gtr:partnerContribution>Provision of anti-IgE and manpower to conduct the experiments</gtr:partnerContribution><gtr:piContribution>Expertise in IgE and clinical trial facilities and patients.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Dr. David Dombrowicz</gtr:description><gtr:id>05F45577-02D8-4C45-89F7-9DDEB544C2DB</gtr:id><gtr:impact>Publications; demonstration of proof of principle for small molecule inhibition of IgE/FceRI interaction for therapeutic intervention in allergic disease, and for recombinant IgE immunotherapy in cancer.</gtr:impact><gtr:partnerContribution>Transgenic mouse models for allergic disease and cancer, and provision of mast cell lines.</gtr:partnerContribution><gtr:piContribution>Expertise in IgE and receptor interactions; functional assays; provision of IgE and other materials for the in vivo studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Los Angeles Institute of Allergy and Clinical Immunology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Professor Toshi Kawakami</gtr:description><gtr:id>AD7DD381-BB56-4767-B582-614AC76BB3F9</gtr:id><gtr:impact>Demonstration that human IgE can exert cytokinergic activity; this has profound implications for the pathogenesis of allergic disease and asthma in particular.</gtr:impact><gtr:partnerContribution>Expertise in analysis of cytokinergic IgE; sequence data.</gtr:partnerContribution><gtr:piContribution>Provision of cDNA of potentially cytokinergic IgE for analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</gtr:department><gtr:description>Dr. Rajat Varma</gtr:description><gtr:id>855CE788-0497-4C64-8916-7CAF5F69BC38</gtr:id><gtr:impact>Paper in preparation; TIRF microscope set up at King's; combination of molecular biology and physics.</gtr:impact><gtr:partnerContribution>EXpertise in artificial bilayer technique</gtr:partnerContribution><gtr:piContribution>Proteins for developing artifical bilayer TIRF microscopy to study protein:protein interactions in the membrane</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Asthma UK Centre in Allergic Mechanisms of Asthma</gtr:department><gtr:description>MRC &amp;amp; Asthma UK Centre in Allergic Mechanisms of Asthma</gtr:description><gtr:id>E42342BA-1067-49D2-B215-8EA7E455EAA7</gtr:id><gtr:impact>Many publications and outputs described in the other sections.</gtr:impact><gtr:partnerContribution>Provision of studentships; support of the Protein Production Facility; network of collaborators for provision of clinical materials from allergic and asthmatic patients.</gtr:partnerContribution><gtr:piContribution>Provision of expertise in molecular, cellular and structural biology across a range of projects.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr. James Spicer</gtr:description><gtr:id>924D6E61-7B12-45BF-A445-E7BCDC94AB6C</gtr:id><gtr:impact>On-going trials of recombinant IgE and IgG antibodies in cancer.</gtr:impact><gtr:partnerContribution>Expertise in translational research in cancer</gtr:partnerContribution><gtr:piContribution>Expertise in recombinant IgE design and production; functional assays and biophysical characterisation of IgE.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southampton General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Immunology</gtr:department><gtr:description>Professor Peter Hawarth</gtr:description><gtr:id>BCE81AC1-1B47-4428-A03B-88CE4ED5AC98</gtr:id><gtr:impact>Multi-disciplinary: molecular biology and clinical medicine</gtr:impact><gtr:partnerContribution>Clinical samples</gtr:partnerContribution><gtr:piContribution>Molecular biology for study of IgE VH regions sequences in atopic and non-atopic asthma.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UCB Collaboration</gtr:description><gtr:id>4E43432A-203B-4944-9204-30FD18529D51</gtr:id><gtr:impact>Work in progress; confidential.</gtr:impact><gtr:partnerContribution>Experience of structure based small molecule drug discovery.</gtr:partnerContribution><gtr:piContribution>Provision of reagents for assay and development of a small molecule inhibitor.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Philippe Gevaert</gtr:description><gtr:id>7B1E7548-CD13-4264-AA02-C751D0641A9B</gtr:id><gtr:impact>Materials generated; posters and talks at meetings; manuscripts in preparation.</gtr:impact><gtr:partnerContribution>Provision of materials and assays</gtr:partnerContribution><gtr:piContribution>Complementary molecular biological assays</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Professor Gideon Lack</gtr:description><gtr:id>032AB6B9-5BA2-4192-9F7C-343B28BEB449</gtr:id><gtr:impact>None yet. Collaboration is multidisciplinary: molecular biology and clinical medicine (paediatric allergy). Gained funding for new MRC Programme Grant (2011-2016).</gtr:impact><gtr:partnerContribution>Provision of clinical material</gtr:partnerContribution><gtr:piContribution>Molecular biology to study peanut allergen-specific IgE response</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Vienna</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>Professor Erika Jensen-Jarolim</gtr:description><gtr:id>6811B435-87FF-482D-88B8-F3044A206DC9</gtr:id><gtr:impact>Several publications; further funding from BRC and CRUK; a clinical trial of a monoclonal IgE (in progress); studentships from BRC.</gtr:impact><gtr:partnerContribution>Two students from the Vienna lab worked at King's on functional studies of chimeric monocloncal IgEs against ovarian and breast cancer.</gtr:partnerContribution><gtr:piContribution>Expertise in IgE function; recombinant DNA technology; materials and facilities for the functional studies, all of which were performed at King's.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Dr. David Dombrowicz</gtr:description><gtr:id>730A6239-3EDB-4223-9918-8C9FFA7DF0F9</gtr:id><gtr:impact>Publications; proof of concept for inhibition of IgE/FceRI for treatment of allergy, and also for monoclonal antibodies in immunotherapy of cancer; development of an animal models.</gtr:impact><gtr:partnerContribution>Transgenic mouse model of allergy and cancer.</gtr:partnerContribution><gtr:piContribution>Material and labour and expertise in IgE, CD23 and FceRI.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanguine Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Professor Robert Aalberse</gtr:description><gtr:id>C55E41D2-8BCC-46BF-BCEB-EB91A8F190F0</gtr:id><gtr:impact>Crystal structure of human IgG4 determined</gtr:impact><gtr:partnerContribution>Provision of purified IgG4 and IgG4-Fc for structural analysis</gtr:partnerContribution><gtr:piContribution>X-ray crystallographic analysis of IgG4 and Fc region.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Dr. Gary Felsenfeld</gtr:description><gtr:id>E3FFC032-C7E1-4FF5-A2DF-45E95443E5CD</gtr:id><gtr:impact>Publications; demonstration that changes in chromatin structure at the IgE locus are responsible for class switching; demonstration of isotype-specific differences in DNA methylation patterns at the IgG and IgE loci.</gtr:impact><gtr:partnerContribution>Expertise in chromatin structure and function, and gene regulation mechanisms; hosting visits from KCL scientists, and post-doctoral worker at NIH.</gtr:partnerContribution><gtr:piContribution>Expertise in molecular biology; assays for gene regulation and synthesis of IgE.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Professor Claus Bachert</gtr:description><gtr:id>46C56A63-2249-4F0A-8446-1619E7F5B467</gtr:id><gtr:impact>Demonstration of receptor revision and isotype switching to IgE in nasal polyps; the demonstration of local IgE switching and production, and the role of bacterial superantigens in the pathogenesis of nasal polyps, will inform future therapeutic intervention.</gtr:impact><gtr:partnerContribution>Provision of clinical material (nasal polyps and turbinates) and manpower for experimental work at King's.</gtr:partnerContribution><gtr:piContribution>Expertise and materials related to IgE regulation and function; functional assays.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London (ICL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>Professor Stephen Durham</gtr:description><gtr:id>379BABF5-9851-4E0A-8344-8E0F00AC789E</gtr:id><gtr:impact>See publication list. Main outcome is the understanding that isotype switching to IgE and production of IgE occurs locally in peripheral tissue. This has major implications for therapeutic intervention in allergic rhinitis and asthma, and also the treatment of non-atopic asthma, since IgE plays a role. Studies of the protective role of IgG4 antibodies in immunotherapy will inform future treatment protocols for this approach.</gtr:impact><gtr:partnerContribution>Access to patient samples, biopsies etc.</gtr:partnerContribution><gtr:piContribution>Expertise in analysing antibody V gene sequences, antibody expression, purification and characterisation; access to facilities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Professor Chris Corrigan</gtr:description><gtr:id>B0F83FE1-8438-44E4-9388-1EBE3638F8BA</gtr:id><gtr:impact>Publications; clinical trial of anti-IgE in non-atopic asthma in progress; demonstrating that IgE plays a role in non-atopic asthma; potential for more effective treatment of this condition.</gtr:impact><gtr:partnerContribution>Provision of clinical materials (bronchial biopsies).</gtr:partnerContribution><gtr:piContribution>Experitse in IgE regulation and function; molecular biology expertise and assays.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Infectious Diseases, Virology Section</gtr:department><gtr:description>Professor Sebastian Johnston</gtr:description><gtr:id>8D463C1C-96EC-44CC-87D5-0CA08D76686D</gtr:id><gtr:impact>None yet. Multidisciplinary: molecular biology and clinical medicine.</gtr:impact><gtr:partnerContribution>Provision of mouse models and clinical materials</gtr:partnerContribution><gtr:piContribution>Molecular biology for studying viral exacerbation of asthma</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr. Pooja Takhar</gtr:description><gtr:id>A03508FC-BDC6-4A16-A66E-8C52F59C799E</gtr:id><gtr:impact>NIHR Fellowship gained.</gtr:impact><gtr:partnerContribution>Expertise in B cell cloning and local IgE synthesis assays</gtr:partnerContribution><gtr:piContribution>Design of experiments to investigate receptor revision and other DNA recombination events involved in isotype switching to IgE. Allergen-specific IgE Fabs derived from this work will be studied by X-ray crystallography.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Graduate School of Biomedical &amp; Health Sciences</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Dermatology</gtr:department><gtr:description>Professor Michihiro Hide</gtr:description><gtr:id>609FF23D-8012-4C57-8502-C6137CA3D1A6</gtr:id><gtr:impact>Paper published (see list)</gtr:impact><gtr:partnerContribution>Cell lines and personnel to carry out confocal microscopy</gtr:partnerContribution><gtr:piContribution>B cell confocal microscopy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Seminars on development of IgE inhibitors for anti-allergy therapy</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>78E1F7D7-09D7-486D-9A2B-EAF05E44D4EE</gtr:id><gtr:impact>Discussions under confidentiality agreements, with various companies, recently UCB-Celltech (UK), AstraZeneca (Sweden) and Pfizer (UK and USA).

Negotiations concluded with one UK-based company; unable to provide further details at present.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sixth Form talks on Asthma, Allergy and Drug Design</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C4B72B26-061B-4550-8961-84CDDFCEF214</gtr:id><gtr:impact>Talks to Sixth Forms, most recently at Magdalen College School, Oxford, and St. Paul's School, London.

Very positive feedback from school staff about pupils' future subject choices at university and career plans. Led to collaborative project with St. Paul's School sixth form; students spend day in lab at King's.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar on novel asthma/allergy therapy development</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EB85AEC3-338C-4DAD-8483-9156478AF2D1</gtr:id><gtr:impact>Presented at several activities organised by Asthma UK aimed at their fundraisers, other supporters and of course including patients.

Raied profiule for our work, and the role of structural biology in the drug discovery process. Enhanced the ability of the charity to engage new donors and raise funds for asthma research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4 Programme</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>60A81F50-2592-4FAA-93E7-1FFB72DD17D0</gtr:id><gtr:impact>Contributed to a BBC Radio Programme on Asthma provision and asthma research: Our Lives in Our Hands - Asthma, Living on a Knife Edge.

Raised profile of the life-threatening aspect of asthma and allergic disease, and of the widespread nature of asthma.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Telephone interviews with journalists</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1406F8D9-17AE-4F08-B4B7-F9C3E82BD212</gtr:id><gtr:impact>Telephone interviews with journalists about our IgE work and development of new drugs. Press releases accompanied recent publication in J. Biol. Chem. Reports in the Times, Daily Telegraph, Daily Mail, London Metro, NHS Web pages.

Raises profile of our work nationally, and of the need for research into allergy and asthma generally.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FF5FF742-E9C1-49FC-A2FE-32A166BD9F06</gtr:id><gtr:impact>Engaged very large number of the public over several hours and generated considerable interest.

Schools visits following discussion at event with teachers.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Asthma UK Website for World Asthma Day</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>05B589A0-3142-488E-8DC3-F7AA4A10BC8C</gtr:id><gtr:impact>Report of our asthma research to develop a novel therapy was highlighted on the website and in publicity material distributed in association with World Asthma Day, 2009.

Raised profile of the need for more research funding and clinical provision for asthma.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sixth Form talks on Asthma, Allergy and Drug Design</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E314E6E3-060A-4D7F-9FE8-DB4B0F4BAE3E</gtr:id><gtr:impact>Most recently to St. Paul's School, London.

Positive feedback from teachers about pupils' university choices and career plans. This talk led to initiation of a project to bring sixth formers into King's to carry out an experiemtnal project involving molecular and structural biology. First run in 2009, the scheme was a great success and will be repeated annually.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newspaper and radio interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>60474246-8E83-48B4-A3D8-CEFB0099D012</gtr:id><gtr:impact>Articles and interviews concerning the trials of IgE in the immunotherapy of cancer

Raised awareness of this approach with the public and assisted in gaining funding.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Telephone interviews with newspapers</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>98762975-A397-4B2A-8D86-B56297A4D194</gtr:id><gtr:impact>Various interviews leading to pieices in newspapers: Times, Daily Telegraph, Sunday Times, Daily Mail, London Metro, NHS Web pages. (Earlier years: breakfast TV appearance and Radio 4 programme &amp;quot;Leading Edge&amp;quot;)

Raised national public profile of allergy research generally.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminars on development of IgE inhibitors</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5E4D022C-2276-48DC-8532-27AF3EE197AF</gtr:id><gtr:impact>Various talks to companies, under confidentiality agreements (UCB Celltech, UK; AstraZeneca, Sweden; Pfizer, UK &amp;amp; USA)

We successfully negotiated an agreement with a company for collaborative development of IgE inhibitors.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentations at Asthma UK events</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6CD7D80A-8DA3-4F12-9647-1A5E2C36BE34</gtr:id><gtr:impact>Presented my research on IgE and the development of novel therapeutics to fundraisers, supporters and patients at events organised by Asthma UK.

Raises profile of asthma research nationally. Assisted the charity in attracting new donors and raising funds for asthma research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newspaper and radio interviews</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A432F4E8-F4F0-429C-AC21-82E68142E9D5</gtr:id><gtr:impact>Articles and interviews concerning the trials of IgE in the immunotherapy of cancer

Raised awareness of this approach with the public and assisted in gaining funding.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centre Public Engagement Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5464B4DE-5881-4CF7-A864-3582B7D2F449</gtr:id><gtr:impact>100 people attended raising the profile of asthma research

Enhanced awareness of need for long-term basic research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC TV Programme</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>09C216FC-54D3-4A98-9F12-3E00FD0CE6A5</gtr:id><gtr:impact>Contribution to BBC TV Series on History of Science

Led to further media interest, interviews etc.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>66378</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Guy's and St Thomas' Biomedical Research Centre</gtr:department><gtr:description>NIHR Biomedical Research Centre</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Guy's and St Thomas' NHS Foundation Trust</gtr:fundingOrg><gtr:id>E0A578BE-E2B9-4D51-B5D7-FAB6C86D6ED4</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>362269</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>BAA3DAAD-F12E-4E48-B34E-FC10A07D53A2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>261554</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's and St. Thomas's Trust Charity, Project Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:id>B78B91A9-C14A-4C4B-909E-43CD7E3E9F1E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>670000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/EPSRC Project Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>88BE5AFE-BCA9-4A41-BC05-673662DAD012</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's and St. Thomas' Charity/Novartis Clinical Trial</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>FEB4CF51-DC50-42DD-88C0-10242356F559</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's and St. Thomas' Charity/Novartis Clinical Trial</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:id>721C7AC4-C529-47A1-93C3-458308D2BE28</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1840000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9D835D4F-753E-4C13-9EF8-24437939A127</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Project Grant</gtr:description><gtr:end>2008-01-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>7464E235-59E5-4233-A4B9-7A24981DC95F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>London Law Fellowship</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>London Law Trust</gtr:fundingOrg><gtr:id>F9FF2ECC-D3F8-46F4-B57C-F57D0D8C646B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FD68B3B1-50E0-4348-A6CE-CFA6A5119A4B</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>468367</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K006142/1</gtr:fundingRef><gtr:id>68B96693-F0EE-4AB4-A642-44FD3DBBDE8D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>205428</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>861D3565-D18D-4A46-A935-1E7E473683A0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>167235</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE award</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>B330B594-40B2-44DB-B669-FC2E813E4C0B</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>167235</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE Award</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K501815/1</gtr:fundingRef><gtr:id>E218A1B1-E6FB-4DF1-BCE9-556472F25AC0</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Guy's and St Thomas' Biomedical Research Centre</gtr:department><gtr:description>Biomedical Research Centre, Programme Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Guy's and St Thomas' NHS Foundation Trust</gtr:fundingOrg><gtr:id>5DA6C15B-567E-41DF-806E-F8269C16010A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>62000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2ACF1AC8-2A9E-4532-8038-B6C1A5CBDEC0</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2323000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4B9A5894-CE52-4F3C-99E5-B9E0A3F5FD8B</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>26000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heptagon Fund</gtr:description><gtr:end>2007-09-02</gtr:end><gtr:fundingOrg>Heptagon Fund</gtr:fundingOrg><gtr:id>C944DF39-F8AC-4F76-BFA2-55648F33DCF6</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>143000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Project Grant</gtr:description><gtr:end>2008-01-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>6954D2BE-FE32-4D96-89CE-294229DD3255</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/GSK Programme Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5B2CBB52-546F-4C04-9C16-36B0B5B6B41E</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship funded by MRC/Asthma UK Centre</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1557C1F9-A8F0-4E31-B990-FD723453FFEF</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>31240</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Foundation Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>153B849C-0F60-4BA1-88AB-2104F2EACBB1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>31000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Collaborative Award/Novartis</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>00319110-BFE9-4DA3-ADAE-41F574889B77</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>62318</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Collaborative Award/Novartis</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3E47E675-0B91-442C-BB6D-902B9413A26A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>C79A6748-747A-4D14-ADF2-1FE279301A1B</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>188422</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Guy's and St Thomas' Biomedical Research Centre</gtr:department><gtr:description>NIHR Biomedical Research Centre Fellowship</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Guy's and St Thomas' NHS Foundation Trust</gtr:fundingOrg><gtr:id>9E6D13E4-9FC4-4354-B032-6BB473E2B399</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>858000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCB Industrial Collaboration</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>UCB Pharma</gtr:fundingOrg><gtr:id>D69EAE42-F478-4E5E-BCD6-856559B1D42B</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Taiwan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD funded by Taiwan Government Scholarship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Government of Taiwan</gtr:fundingOrg><gtr:id>364C48E3-0786-4C38-8234-0679DEC406F9</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship funded by MRC/Asthma UK Centre</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>19688D65-0515-4440-9AC4-3EEFD4DA8B78</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1687570</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital Investment Award</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>37A9B768-4B7B-4909-9ED0-6975BFA4736E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>152756</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCB Celltech</gtr:department><gtr:description>UCB Industrial Collabration</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>UCB Pharma</gtr:fundingOrg><gtr:id>4D8523B5-B50B-450A-B672-3DC2BCD17BD7</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK Project Grant</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>3D2022D5-B8CC-4609-9054-C8D80D763289</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>BBB3FD8A-504C-417F-8B67-A6D606E3A168</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>458250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>A6F7C4F9-C5D3-409E-9AD3-1A38322CE183</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>64915E10-B872-4FD3-BDB4-9D43B85865FD</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/GSK Programme Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>DAA92C63-A7A0-4021-9392-5187AE5C1476</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Research Award</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B313EF0E-9C00-4DD2-86B1-90E22E5F4465</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship funded by MRC/Asthma UK Centre</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>94C31E84-EE53-461B-84C8-C192CF06A3CF</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49956</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>VIP Award</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>43047E17-EBA9-40F1-B11A-798282015ED4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Antibody capable of binding high molecular weight melanoma associated antigen and also to Fc-epsilon receptor, with application to cancer therapy.</gtr:description><gtr:id>1CF60768-3AA2-4711-AAE0-08A29CE7357C</gtr:id><gtr:impact>Too early to report.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2013050725</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>IgE anti-HMW-MAA antibody patent</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Set of optimised expression vectors for the production of whole human antibodies.</gtr:description><gtr:id>CA5D7248-D621-4C01-B24D-5C4D76637116</gtr:id><gtr:impact>Expression system used for production of human antibodies in various applications supporting projects relating to the use of IgE in cancer therapy, and also studies of cytokinergic IgE.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2009150426</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Expression system for antibodies</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Production of IgE monoclonal antibody against a melanoma-associated antigen</gtr:description><gtr:id>4DB270DA-74AA-43A0-B029-6FC1D66E8D6C</gtr:id><gtr:impact>Too early to report.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>Insufficient Information</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>IgE antibodies against melanoma antigen</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Asthma UK Research Grants Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E8B8D2E4-A1C1-4DAD-81BC-375702338EF0</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Asthma UK Consultation on Basic Asthma Research Strategy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DB0D070D-7EB1-41EA-A4B7-0BFDFCE2E9C7</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Asthma UK Research Strategy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AC4D35A8-C85F-4D57-BDE0-5C56490074AB</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Asthma UK Consultation on Basic Asthma Research Strategy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>57A7BCF9-02A7-4591-9982-53EB9C6C71B5</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Improved cell lines producing various IgE antibodies for immunotherapy of cancer (ovarian and breast).</gtr:description><gtr:id>D8B05C84-F8B3-4E49-9989-747A478ED765</gtr:id><gtr:impact>On-going trials of IgE for cancer immunotherapy</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IgE-producing cell line</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Novel antibody expression vectors for producing chimeric human antibodies of any isotype.</gtr:description><gtr:id>A70695C8-37C5-4B64-8782-DE7ACD50BD31</gtr:id><gtr:impact>Has been used to produce chimeric IgE antibodies for anti-cancer immunotherapy.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IgE expression system</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>X-ray crystal structure at high resolution of IgE-Fc (PDB code 2wqr), and also the structure of the complex with receptor.</gtr:description><gtr:id>7969115D-6197-462B-9079-606F1C67041F</gtr:id><gtr:impact>The structural data reveal conformational changes that can be targetted in the design of an allosteric inhibitor of the IgE/receptor interaction. A drug discovery programme is in progress, both in-house and as an industrial collaboration.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Structure of IgE-Fc and receptor complex</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=2WQR</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Small molecule inhibitors of the IgE/receptor interaction.</gtr:description><gtr:id>7B8834B7-E752-46B8-84EC-366B512F20D3</gtr:id><gtr:impact>Basis for a drug discovery programme; collaboration with industrial partner.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IgE inhibitors</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Crystal structure of IgE-Fc. Coordinates deposited in the Protein Data Bank code 2wqr.</gtr:description><gtr:id>9E658E70-21AE-4072-B654-8CB2E93BCC22</gtr:id><gtr:impact>This structure of IgE-Fc revealed the molecule to be acutely bent, and this led to understanding that allosteric approaches to inhibiting IgE activity might be possible.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IgE-Fc crystal structure</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=2WQR</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse or human V region sequences are incorporated into a complete human antibody of any isotype for rapid expression.</gtr:description><gtr:id>86BB9E6F-4071-46C6-91BE-E742C77026C6</gtr:id><gtr:impact>Patent applications in US and UK are under consideration</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Rapid antibody expression system</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Transgenic mouse model for intervention in allergic disease and for immunotherpy for cancer.</gtr:description><gtr:id>B309109A-FA07-4287-8FE8-EE436C01077B</gtr:id><gtr:impact>On-going development programme for small molecule inhibitors of IgE/receptor interactions in allergy, and on-going trials of IgE in cancer immunotherapy.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mouse model for allergy and cancer immunotherapy</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Crystal structure of IgE-Fc determined at high resolution (1.9 Angstroms); valuable for anti-IgE drug discovery; PDB code 2WQR</gtr:description><gtr:id>BAC914D1-E40F-48DD-B386-36F3F4ED860B</gtr:id><gtr:impact>This structure has enabled in silico and rational design of anti-IgE inhibitors, which are currently being evaluated.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>High resolution IgE-Fc structure</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=2WQR</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Transgenic mouse model for intervention in allergic disease and immunotherapy of cancer.</gtr:description><gtr:id>06AD14DE-4287-4388-B674-02709D6BDEA0</gtr:id><gtr:impact>On-going development programme for small molecule inhibitors of IgE/receptor interactions in allergy, and on-going trials of IgE in cancer immunotherapy.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transgenic mouse model for allergy and cancer</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Sequences of VH genes associated with IgE antibodies from allergic patients.</gtr:description><gtr:id>53735BFD-6929-45BA-968E-475D2166473A</gtr:id><gtr:impact>These sequences contribute to understanding the repertoire of IgE antibodies in allergic patients, from which the allergen or superantigenic causative agent may be identified. Other expected outcomes are: understanding receptor revision and other DNA recombination events involved in IgE class switching; the structural basis of cytokinergic activity.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>VH gene sequences</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Generated rat MOV18 monocloncal antibody to folate binding protein; WAG rat cell line that expresses human folate binding protein; application to tracking pharmacokinetics of IgE antibody.</gtr:description><gtr:id>7A238C7F-56F8-4572-B257-8E40AA1DCC4A</gtr:id><gtr:impact>Too early - experiments in progress.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Rat model for immunotherapy of cancer</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new tool for identifying sequences for use in generating FISH probes; here used for the analysis of spatial and temporal events involved in class switching to IgE in human B cells by confocal microscopy.</gtr:description><gtr:id>AB8790B2-E55F-4ACE-A1BE-FE67D2B021F9</gtr:id><gtr:impact>Exploitation of this technology is in progress; yet to be published.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Bioinformatics tools for identification of FISH probes</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Fluorescently labelled versions of IgE-Fc that are sensitive to conformational changes in the IgE molecule. Valuable for screening for small molecules that influence the structure of IgE and that might therefore be leads for IgE inhibitors.</gtr:description><gtr:id>764284DD-B01C-4596-AE68-7CFE190B870E</gtr:id><gtr:impact>Currently under investigation within our group; publications in preparation; potential IgE small molecule inhibitors.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Fluorescently labelled IgE biosensors</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Three colour flow cytometric assay to distinguish phagocytic activity from cytotoxic activity in ADCC in tumour cells.</gtr:description><gtr:id>3D7527AA-4A18-40D6-8F40-922629026FF0</gtr:id><gtr:impact>The method has revealed the mechanism of IgE antibody dependent tumour cell killing, and has led to the initiation of clinical trials.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Flow cytometric assay for phagocytic/cytotoxic activity</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Allergen-specific IgG4 blocking antibodies for amelioration of allergic response.</gtr:description><gtr:id>0473D025-0B44-46BB-804C-5323950C0B4A</gtr:id><gtr:impact>Gained MRC Programme Grant and Fellowship (London Law &amp;amp; NIHR BRC) support to develop these antibodies in a therapeutic context.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IgG4 blocking antibodies</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Improved cell lines producing IgE antibodies</gtr:description><gtr:id>E3CB380D-42D3-40C4-B82F-DDAE6B8A2C0A</gtr:id><gtr:impact>Ongoing trials of IgE for cancer immunotherapy</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cell lines producing recombinant IgE</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>TIRF microscopy set up to study lipid bilayers incorpotating membrane proteins, in order to study co-crosslinking of these membrane proteins; will be used to study mIgE and CD23 and CD21.</gtr:description><gtr:id>9015CB99-F2AF-48CC-875C-1CD1F5B03870</gtr:id><gtr:impact>Too early - experiments in progress.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TIRF microscope</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E294231-3F58-46CF-8F3E-C3095C4D33C5"><gtr:id>3E294231-3F58-46CF-8F3E-C3095C4D33C5</gtr:id><gtr:title>Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of Fc?RI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e44fb66149f0e8d06df5576a12fbcaf0"><gtr:id>e44fb66149f0e8d06df5576a12fbcaf0</gtr:id><gtr:otherNames>Rudman SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ADAF81D4-AF28-42F6-B3D4-975529E87A72"><gtr:id>ADAF81D4-AF28-42F6-B3D4-975529E87A72</gtr:id><gtr:title>Comprehensive FISH probe design tool applied to imaging human immunoglobulin class switch recombination.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db4874384846dee1ab627dad2682602b"><gtr:id>db4874384846dee1ab627dad2682602b</gtr:id><gtr:otherNames>Nedbal J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/33BACC17-461B-4839-88AA-ADEDB528EF97"><gtr:id>33BACC17-461B-4839-88AA-ADEDB528EF97</gtr:id><gtr:title>Germinal-centre reactions in allergic inflammation.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d366311edfeaa1ca0c49c81e1c1a6e0a"><gtr:id>d366311edfeaa1ca0c49c81e1c1a6e0a</gtr:id><gtr:otherNames>Gould HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4EA0431-B74E-4CB2-BDD1-B2743DD2DCAE"><gtr:id>D4EA0431-B74E-4CB2-BDD1-B2743DD2DCAE</gtr:id><gtr:title>Total synthesis of (+/-)-aspercyclide A and its C19 methyl ether.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42b9baf75965bce08cbac00451a852fd"><gtr:id>42b9baf75965bce08cbac00451a852fd</gtr:id><gtr:otherNames>Carr JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7932E266-2383-4C95-8D89-30F695336E35"><gtr:id>7932E266-2383-4C95-8D89-30F695336E35</gtr:id><gtr:title>Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0b1480f9c31d6e8295beb745262209f5"><gtr:id>0b1480f9c31d6e8295beb745262209f5</gtr:id><gtr:otherNames>Takhar P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/63454551-8279-4F62-8924-62FA7E798276"><gtr:id>63454551-8279-4F62-8924-62FA7E798276</gtr:id><gtr:title>Epidemiological associations of allergy, IgE and cancer.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f5cf125bb61b8a825e1364b81e3ebd6"><gtr:id>3f5cf125bb61b8a825e1364b81e3ebd6</gtr:id><gtr:otherNames>Josephs DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C2AED5F-4867-49A1-A12D-F19E4EDB9592"><gtr:id>6C2AED5F-4867-49A1-A12D-F19E4EDB9592</gtr:id><gtr:title>Basis of the intrinsic flexibility of the Ce3 domain of IgE.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ab9dd681c7861cbaa73d34677709afe"><gtr:id>4ab9dd681c7861cbaa73d34677709afe</gtr:id><gtr:otherNames>Borthakur S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/926B8497-2238-45E3-B19C-42BB3FF84119"><gtr:id>926B8497-2238-45E3-B19C-42BB3FF84119</gtr:id><gtr:title>A monomeric chicken IgY receptor binds IgY with 2:1 stoichiometry.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/634c4d2f0dcfa06b57dcd675a9bf88ae"><gtr:id>634c4d2f0dcfa06b57dcd675a9bf88ae</gtr:id><gtr:otherNames>Taylor AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A0E6003C-36EE-4153-A89C-30D6795F8BC7"><gtr:id>A0E6003C-36EE-4153-A89C-30D6795F8BC7</gtr:id><gtr:title>Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ede4275b908f595b76b00cddaa614c7"><gtr:id>4ede4275b908f595b76b00cddaa614c7</gtr:id><gtr:otherNames>Chen JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE38F34E-9362-4EFB-8734-F777A35C54B7"><gtr:id>BE38F34E-9362-4EFB-8734-F777A35C54B7</gtr:id><gtr:title>Allergy and Allergic Diseases</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb22ceeb4acdb2e96a0409fdf122e293"><gtr:id>cb22ceeb4acdb2e96a0409fdf122e293</gtr:id><gtr:otherNames>Sutton B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:isbn>9781405157209</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C94DD36-1491-4EAD-B8F3-635E733CF687"><gtr:id>6C94DD36-1491-4EAD-B8F3-635E733CF687</gtr:id><gtr:title>Synthesis of the C19 methyl ether of aspercyclide A via germyl-Stille macrocyclisation and ELISA evaluation of both enantiomers following optical resolution.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42b9baf75965bce08cbac00451a852fd"><gtr:id>42b9baf75965bce08cbac00451a852fd</gtr:id><gtr:otherNames>Carr JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/438524CE-283A-472E-806F-AF3A45B32BD0"><gtr:id>438524CE-283A-472E-806F-AF3A45B32BD0</gtr:id><gtr:title>The who, where, and when of IgE in allergic airway disease.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98c3af7830806528f76d378e70b8c7dd"><gtr:id>98c3af7830806528f76d378e70b8c7dd</gtr:id><gtr:otherNames>Dullaers M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AC655137-2A64-4430-94C9-23D3B7D98620"><gtr:id>AC655137-2A64-4430-94C9-23D3B7D98620</gtr:id><gtr:title>Mucosal tissue polyclonal IgE is functional in response to allergen and SEB.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/521a12116f77e6da61285a2e50e32218"><gtr:id>521a12116f77e6da61285a2e50e32218</gtr:id><gtr:otherNames>Zhang N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6BD45522-A0F5-4C75-93AD-556CC1A1E735"><gtr:id>6BD45522-A0F5-4C75-93AD-556CC1A1E735</gtr:id><gtr:title>Conformational plasticity at the IgE-binding site of the B-cell receptor CD23.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a1cd44326634381f2c4a83a751b43ea0"><gtr:id>a1cd44326634381f2c4a83a751b43ea0</gtr:id><gtr:otherNames>Dhaliwal B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FA04BDC6-9945-4ACC-AC1B-6E0E238BB7B0"><gtr:id>FA04BDC6-9945-4ACC-AC1B-6E0E238BB7B0</gtr:id><gtr:title>Ontogeny of human IgE-expressing B cells and plasma cells.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/abff5f3c583fc3f81163ddc836927686"><gtr:id>abff5f3c583fc3f81163ddc836927686</gtr:id><gtr:otherNames>Ramadani F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A9DB419-B628-4E9E-9BA0-173958EC977C"><gtr:id>7A9DB419-B628-4E9E-9BA0-173958EC977C</gtr:id><gtr:title>The crystal structure of rabbit IgG-Fc.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c60c1670c61ad56cb052a51980e03a36"><gtr:id>c60c1670c61ad56cb052a51980e03a36</gtr:id><gtr:otherNames>Girardi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E522A0A-E540-462C-8381-FC4CE75746DA"><gtr:id>6E522A0A-E540-462C-8381-FC4CE75746DA</gtr:id><gtr:title>Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a9e46450847bc63d817ad16c0a2311cb"><gtr:id>a9e46450847bc63d817ad16c0a2311cb</gtr:id><gtr:otherNames>Badar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D1EB48E-2AA2-4AB1-90DC-DB31C4307AD5"><gtr:id>5D1EB48E-2AA2-4AB1-90DC-DB31C4307AD5</gtr:id><gtr:title>Mutations in an avian IgY-Fc fragment reveal the locations of monocyte Fc receptor binding sites.</gtr:title><gtr:parentPublicationTitle>Developmental and comparative immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/634c4d2f0dcfa06b57dcd675a9bf88ae"><gtr:id>634c4d2f0dcfa06b57dcd675a9bf88ae</gtr:id><gtr:otherNames>Taylor AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0145-305X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18D71BD1-036F-47BC-9FB8-C08100050580"><gtr:id>18D71BD1-036F-47BC-9FB8-C08100050580</gtr:id><gtr:title>High resolution analysis of the chromatin landscape of the IgE switch region in human B cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7568958c1469c3977509571c8cc9d26c"><gtr:id>7568958c1469c3977509571c8cc9d26c</gtr:id><gtr:otherNames>Dayal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F905847-977D-41E7-8998-A34AD16F2CF2"><gtr:id>0F905847-977D-41E7-8998-A34AD16F2CF2</gtr:id><gtr:title>Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor Fc?RI.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/912538b3960e48e1db262c7f0859431b"><gtr:id>912538b3960e48e1db262c7f0859431b</gtr:id><gtr:otherNames>Holdom MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B1562C3-5402-49E6-A896-1851AE0ED21C"><gtr:id>7B1562C3-5402-49E6-A896-1851AE0ED21C</gtr:id><gtr:title>Ca2+-dependent structural changes in the B-cell receptor CD23 increase its affinity for human immunoglobulin E.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ce305de8784b1832b40dbf75ddb4b84"><gtr:id>2ce305de8784b1832b40dbf75ddb4b84</gtr:id><gtr:otherNames>Yuan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/35059711-1A6B-43C7-A3E4-DB1EEB6B8D9D"><gtr:id>35059711-1A6B-43C7-A3E4-DB1EEB6B8D9D</gtr:id><gtr:title>IgE in allergy and asthma today.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d366311edfeaa1ca0c49c81e1c1a6e0a"><gtr:id>d366311edfeaa1ca0c49c81e1c1a6e0a</gtr:id><gtr:otherNames>Gould HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4D72B337-61AC-4401-952B-C6B29FE63830"><gtr:id>4D72B337-61AC-4401-952B-C6B29FE63830</gtr:id><gtr:title>Soluble CD23 controls IgE synthesis and homeostasis in human B cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4726c27867b62772e7873f5ec3ae3e94"><gtr:id>4726c27867b62772e7873f5ec3ae3e94</gtr:id><gtr:otherNames>Cooper AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F227ED50-8449-42F4-82D6-05B7711AD042"><gtr:id>F227ED50-8449-42F4-82D6-05B7711AD042</gtr:id><gtr:title>Avian IgY binds to a monocyte receptor with IgG-like kinetics despite an IgE-like structure.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/634c4d2f0dcfa06b57dcd675a9bf88ae"><gtr:id>634c4d2f0dcfa06b57dcd675a9bf88ae</gtr:id><gtr:otherNames>Taylor AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CE4AEE72-CFAD-4F2C-A81B-3731D0442C48"><gtr:id>CE4AEE72-CFAD-4F2C-A81B-3731D0442C48</gtr:id><gtr:title>The crystal structure of an avian IgY-Fc fragment reveals conservation with both mammalian IgG and IgE.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/634c4d2f0dcfa06b57dcd675a9bf88ae"><gtr:id>634c4d2f0dcfa06b57dcd675a9bf88ae</gtr:id><gtr:otherNames>Taylor AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7384698B-C187-4AB7-A592-5ADC467441E9"><gtr:id>7384698B-C187-4AB7-A592-5ADC467441E9</gtr:id><gtr:title>Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ab77dfaf234f344938c4c69dd258d0b4"><gtr:id>ab77dfaf234f344938c4c69dd258d0b4</gtr:id><gtr:otherNames>Gilbert AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53274116-5B10-4816-9941-7FC66A7E6B33"><gtr:id>53274116-5B10-4816-9941-7FC66A7E6B33</gtr:id><gtr:title>Analysis of intergenic transcription and histone modification across the human immunoglobulin heavy-chain locus.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5b6c9ebd29f3dcd893759126a2cab4e6"><gtr:id>5b6c9ebd29f3dcd893759126a2cab4e6</gtr:id><gtr:otherNames>Chowdhury M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4994FCDF-31C2-4EFB-8EEF-3F656AA50001"><gtr:id>4994FCDF-31C2-4EFB-8EEF-3F656AA50001</gtr:id><gtr:title>Allergy and Allergic Diseases</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7fa57244cbf713751fc1abeabc4956c"><gtr:id>a7fa57244cbf713751fc1abeabc4956c</gtr:id><gtr:otherNames>Gould H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:isbn>9781405157209</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3769960-F911-42D9-A795-8F8C3AF97601"><gtr:id>E3769960-F911-42D9-A795-8F8C3AF97601</gtr:id><gtr:title>Attenuation of IgE affinity for FcepsilonRI radically reduces the allergic response in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/61ae9f5c2fa4c3ea7eb9b15c9500d1f0"><gtr:id>61ae9f5c2fa4c3ea7eb9b15c9500d1f0</gtr:id><gtr:otherNames>Hunt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/108874F9-CA6D-4B48-A92F-D981E1970C03"><gtr:id>108874F9-CA6D-4B48-A92F-D981E1970C03</gtr:id><gtr:title>Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c11f0fc7f828a365a5b00dfb947462a"><gtr:id>1c11f0fc7f828a365a5b00dfb947462a</gtr:id><gtr:otherNames>Karagiannis SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F82E8FC-EC72-43D2-A6AE-094A8C93523F"><gtr:id>9F82E8FC-EC72-43D2-A6AE-094A8C93523F</gtr:id><gtr:title>AllergoOncology: the role of IgE-mediated allergy in cancer.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97f8f42df40afcf8943e0fbac65d1b90"><gtr:id>97f8f42df40afcf8943e0fbac65d1b90</gtr:id><gtr:otherNames>Jensen-Jarolim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/51695911-94E3-450C-B07F-90DD74601B1A"><gtr:id>51695911-94E3-450C-B07F-90DD74601B1A</gtr:id><gtr:title>Human IgG4: a structural perspective.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d113a1d20fe106ce208a0bf8036d73c"><gtr:id>4d113a1d20fe106ce208a0bf8036d73c</gtr:id><gtr:otherNames>Davies AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6623D2B6-ED56-4CB0-B382-CEAE552A9497"><gtr:id>6623D2B6-ED56-4CB0-B382-CEAE552A9497</gtr:id><gtr:title>Detection of refractive index changes in individual living cells by means of surface plasmon resonance imaging.</gtr:title><gtr:parentPublicationTitle>Biosensors &amp; bioelectronics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d7a568e7788682ba49f66d2b66af3a4"><gtr:id>9d7a568e7788682ba49f66d2b66af3a4</gtr:id><gtr:otherNames>Yanase Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0956-5663</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3BC7B479-1803-4564-8C83-CB6FF66B8510"><gtr:id>3BC7B479-1803-4564-8C83-CB6FF66B8510</gtr:id><gtr:title>Structure and dynamics of IgE-receptor interactions: FceRI and CD23/FceRII.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/451674ad6bba3e011a22f8fc97def04f"><gtr:id>451674ad6bba3e011a22f8fc97def04f</gtr:id><gtr:otherNames>Sutton BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501494</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>